The EMA’s CHMP issued positive opinions for two orphan drugs, including Minoryx’s cALD therapy after a prior rejection, while also delivering a setback to Zevra Therapeutics. CHMP backed Minoryx’s development following earlier hurdles, but it adopted a negative opinion for Zevra’s arimoclomol for Niemann-Pick disease type C, despite US FDA approval for a related product.